Corrona's longitudinal, deep clinical data sets provide a unique, real time, representative view of 'state of the disease' management in the dynamic and evolving global marketplace.
Longitudinal data provides insight as to how patients cycle through medications and as to the factors influencing providers' treatment decisions.
Survival analyses are performed that look at treatment persistency and reasons for medication switching and discontinuation.
Burden of Illness and Unmet Need.
Examination of disease activity and lack of response to therapies can identify the burden of illness and unmet need of autoimmune patient populations.
Quality of Care.
Prescribing practices are examined including whether providers are following a treat-to-target treatment paradigm.
Patient Centered Research.
Understanding the patient's experience is pursued through the evaluation of patient reported outcomes.
Treatment & Comparative Effectiveness.
Treatment effectiveness and comparative effectiveness by drug, between classes of drugs and within classes of drugs using validated outcome measures.
Analyses identify subgroups of patients who will have better responses a particular drug class as compared to competitors.
Protected Health Information (PHI) Linkage.
Corrona's PHI enables linking deep clinical data with other sources such as Medicare, National Death Index and other dataset such as claims and labs at an individual level.
Gain key insights from regulatory-grade, highly structured data.
Deep clinical data and standardized outcome measures inform the needs of industry.
Corrona gathers data specifically designed to capture factors associated with medication choice and switching therapies, informing manufacturers' positioning within the competitive landscape.
Corrona's robust longiutudinal data uncovers utilization trends, which can answer your market-related questions.
Comparative Effectiveness and Safety.
Breadth and depth of comparator cohorts within the highly structured, longitudinal data set supports comparative analyses of classes of drugs as well as head-to-head analyses.